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Beta (b)-blockers are widely used in the treatment of cardiovascular disease but are well
recognised for causing bronchoconstriction in asthmatic subjects. The third-generation car-
dio-selective b-blocker celiprolol is a selective b1-adrenergic blocking agent with b2-agonist
properties and would therefore be a preferred b-blocker if an asthmatic subject required treat-
ment with b-blockers for cardiovascular disease. We present the case of a 79-year-old man with
ischaemic heart disease and hypertension but no preceding respiratory disease who developed
significant bronchoconstriction on celiprolol, which resolved completely on drug cessation alone
with no relapse of respiratory symptoms two years after cessation of treatment.
ª 2008 Published by Elsevier Ltd.Introduction
b-blockers are widely used in the treatment of cardiovas-
cular disease, including hypertension, angina, myocardial
infarction, arrhythmias and heart failure. b-blockers bind
to b-adrenoceptors, thereby blocking the effects of
epinephrine and norepinephrine. Some b-blockers, not only
prevent binding of sympathoamines to the b-adrenoceptor
but also partially activate the b-adrenoceptor, and are thus
said to possess intrinsic sympathomimetic activity (ISA).
Early b-blockers are non-selective, in that they block
both b-1 (cardiac) and b-2 (bronchial) adrenoceptors and
can lead to unwanted b-2-blockade effects such as airflow
obstruction. Newer b-blockers such as celiprolol are7288 5353; fax: þ44 20 7288 50
hittington.nhs.uk (H.M. Branley)
lsevier Ltd.relatively cardio-selective but are not cardio-specific. Cel-
iprolol additionally possesses vasodilator properties
through blockade of vascular alpha-adrenoceptors.
Celiprolol has been widely reported as being non-bron-
choconstrictive both in subjects with asthma1,2 and
propranolol-induced bronchoconstriction.3,4
We report a case of significant bronchospasm in a patient
taking celiprolol with no previous history of airway disease,
which resolved completely on cessation of the drug.
Case report
A 79-year-old man presented with a 3-year history of
wheeze, especially at night. There was no dyspnoea or60.
.
Figure 1 (a) PEFR diary on celiprolol demonstrating significant (35%) diurnal PEFR variation; (b) PEFR diary off celiprolol
demonstrating non-significant (9%) diurnal PEFR variation.
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years’ consumption. He had ischaemic heart disease and
hypertension, for which he took celiprolol 200 mg twice
daily and had been for the preceding 10 years. There was
no history of atopic disease, no family history of asthma and
he had no occupational exposures.
Physical examination revealed a clear chest with normal
breath sounds and no added sounds. Peak expiratory flow
rate (PEFR) 274 L/min. Spirometry did not demonstrate
airflow obstruction with forced expiratory volume in 1 s
(FEV1) 2.04 L, forced vital capacity (FVC) 2.24 L (ratio 91%).
Chest X-ray revealed a cardiothoracic ratio of 18/29 cm
with clear lung fields.
A PEFR diary [Fig. 1(a)], whilst continuing celiprolol,
showed a peak of 460 L/min and trough of 300 L/min
(diurnal variation 35%). Following this observation, cel-
iprolol was stopped and a repeat PEFR diary [Fig. 1(b)] was
recorded after cessation of celiprolol for 3 months. This
showed a peak of 460 L/min and trough of 420 L/min
(diurnal variation 9%). Coincident with this improvement in
PEFR was complete resolution of all respiratory symptoms.
During a 2-year period of follow-up there was no recurrence
of any respiratory symptoms.Discussion
b-blocker induced bronchoconstriction in asthma is widely
reported, even with the cardio-selective b-blocker ateno-
lol.5e7 However, b-blocker induced bronchoconstriction in
non-asthmatic subjects is exceedingly rarely reported and
then, only with non-cardio-selective agents such as
propranolol.8,9 To the best of our knowledge there are no
reported cases of celiprolol-induced bronchoconstriction in
non-asthmatic subjects. In fact, celiprolol has been
widely reported as being non-bronchoconstrictive both
in subjects with asthma1,2 and propranolol-induced
bronchoconstriction.3,4
What makes this case even more interesting is that
celiprolol is regarded as providing a greater margin of
respiratory safety than other cardio-selective b-blockers7
due to its b2 agonist and intrinsic sympathomimetic activity
(ISA).
Celiprolol is a third-generation b-adrenoceptor blocker
with selective b-1-antagonist, partial b-2-agonist and mild
alpha-2-antagonist actions, with less risk of vasoconstric-
tion, bronchoconstriction and myocardial depression due to
Celiprolol-induced bronchospasm 143its ISA. Whilst not being previously described as causing
bronchoconstriction, celiprolol is reported to cause hyper-
sensitivity pneumonitis with a lymphocytic alveolitis, which
resolves completely on celiprolol cessation.10
When celiprolol is directly compared to another cardio-
selective b-blocker (atenolol) in asthmatic subjects, it has
been shown that atenolol is associated with bronchocon-
striction but that there is no difference in day-to-day
asthma control, as judged by PEFR diary, inhaler use and
symptom scores.7
Our patient fulfilled the criteria for diagnosing asthma
according to the British Thoracic Society/Scottish Inter-
collegiate Guidelines Network (BTS/SIGN) British guide-
line on the management of asthma 2008. There was
significant diurnal variation in PEFR clearly demonstrated
whilst taking celiprolol, which completely resolved on
cessation of the drug. Follow-up for 2 years of celiprolol
failed to demonstrate any recurrence of respiratory
symptoms.
One common feature of most published data involving
b-blocker usage in asthma is the relatively small number of
patients recruited in each study, emphasising the need for
a larger scale study in this area.
Conclusions
We present the first case of celiprolol-induced broncho-
spasm in a non-asthmatic subject, which resolved
completely on celiprolol cessation alone. Although cel-
iprolol is cardio-selective we would still urge caution and
close observation for the development of respiratory
adverse effects when initiating cardio-selective
b-blockers, even in patients without a preceding history of
Asthma.
We would also like to emphasise that the development
of respiratory symptoms can be delayed, and hence the
need to consider drugs in new onset respiratory
symptoms.
Learning points
 b-blocker induced bronchospasm can develop in non-
asthmatic patients even with cardio-selective agents
such as celiprolol. The onset of adverse effects from b-blockers is not
necessarily temporally related to the initiation of
treatment.Conflict of interest statement
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